Combretastatin A-1
 | |
| Names | |
|---|---|
| IUPAC name
3-Methoxy-6-[(E)-2-(3,4,5-trimethoxyphenyl)ethenyl]benzene-1,2-diol | |
| Other names
Combretastatin A1; OXi4500 | |
| Identifiers | |
109971-63-3  | |
| ChEMBL | ChEMBL520204  |
| ChemSpider | 4800178 |
| |
| Jmol-3D images | Image |
| PubChem | 6078282 |
| |
| Properties | |
| Molecular formula |
C18H20O6 |
| Molar mass | 332.35 g·mol−1 |
| Except where noted otherwise, data is given for materials in their standard state (at 25 °C (77 °F), 100 kPa) | |
| verify (what is: /?) | |
| Infobox references | |
Combretastatin A-1 is a combretastatin and a stilbenoid. It can be found in Combretum caffrum, the Eastern Cape South African Bushwillow tree.[1]
It is an antiangiogenic agent acting by destabilizing tubulin, which induces cell apoptosis of proliferating endothelial cells.[1]
Currently designated an orphan drug by the FDA, combretastatin A1 diphosphate (OXi4503 or CA1P) is in Phase I clinical trials for relapsed and refractory acute myeloid leukemia and myelodysplastic syndrome.[2]
References
- ↑ 1.0 1.1 Pettit, G. R.; Singh, S. B.; Niven, M. L.; Hamel, E.; Schmidt, J. M. (1987). "Isolation, Structure, and Synthesis of Combretastatins A-1 and B-1, Potent New Inhibitors of Microtubule Assembly, Derived from Combretum caffrum". Journal of Natural Products 50 (1): 119–131. doi:10.1021/np50049a016. PMID 3598594.
- ↑ http://clinicaltrials.gov/ct2/show/NCT01085656
| ||||||||||||||||||||||||||||||||||||||||||||||||||||